iomeprol has been researched along with Metabolic Syndrome in 1 studies
iomeprol: structure given in first source
iomeprol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, S | 1 |
| Shin, H | 1 |
| Lee, Y | 1 |
| Yoon, JW | 1 |
| Kang, SM | 1 |
| Choi, SH | 1 |
| Park, KS | 1 |
| Jang, HC | 1 |
| Choi, SI | 1 |
| Chun, EJ | 1 |
1 other study available for iomeprol and Metabolic Syndrome
| Article | Year |
|---|---|
Effect of metabolic syndrome on coronary artery stenosis and plaque characteristics as assessed with 64-detector row cardiac CT.
Topics: Adult; Aged; Anthropometry; Calcinosis; Chi-Square Distribution; Contrast Media; Coronary Artery Dis | 2011 |